4.5 Article

Insomnia Moderates the Relationship Between Amyloid-β and Cognitive Decline in Late-Life Adults without Dementia

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 81, 期 4, 页码 1701-1710

出版社

IOS PRESS
DOI: 10.3233/JAD-201582

关键词

Amyloid-beta; cognition; insomnia; interaction; longitudinal

资金

  1. National Natural Science Foundation of China [82001136, 81901121]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  24. Johnson & Johnson Pharmaceutical Research & Development LLC.
  25. Lumosity
  26. Lundbeck
  27. Merck Co., Inc.
  28. Meso Scale Diagnostics, LLC.
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer Inc.
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research

向作者/读者索取更多资源

Insomnia may modulate the relationship between amyloid-beta and cognitive performance in older adults, with individuals having elevated A beta and insomnia experiencing faster cognitive decline.
Background: It is suggested that not all individuals with elevated A beta will develop dementia or cognitive impairment. Environment or lifestyle might modulate the association of amyloid pathology with cognition. Insomnia is a risk factor of cognitive disorders including Alzheimer's disease. Objective: To investigate if insomnia moderated the relationship between amyloid-beta (A beta) and longitudinal cognitive performance in non-demented elders. Methods: A total of 385 Alzheimer's Disease Neuroimaging Initiative participants (mean age = 73 years, 48% females) who completed 4 + neuropsychological evaluations and a [F-18] florbetapir positron emission tomography scan were followed up to 8 years. Linear mixed-effects regression models were used to examine the interactions effect between insomnia and A beta on longitudinal cognitive sores, including four domains (memory [MEM], executive function [EF], language [LAN], and visuospatial function [VS]). Results: The A beta-positive status (A+) but not insomnia independently predicted faster cognitive decline in all domains. Furthermore, the relationship between A beta and cognitive decline was moderated by insomnia (MEM: chi(2) = 4.05, p = 0.044, EF: chi(2) = 4.38, p = 0.036, LAN: chi(2) = 4.56, p = 0.033, and VS: chi(2) = 4.12, p = 0.042). Individuals with both elevated A beta and insomnia experienced faster cognitive decline than those with only elevated A beta or insomnia. Conclusion: These data reinforced the values of insomnia management in preventing dementia, possibly by interacting A beta metabolism. Future efforts are warranted to determine whether sleep improvement will postpone the onset of dementia, specifically among populations in stages of preclinical or prodromal AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据